Search

Vanadium

Opicapone

Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase

Pozelimab

[A261120] Pozelimab is a human, monoclonal immunoglobulin G4^P antibody against the terminal complement protein C5. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

Marstacimab

[L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant. … [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency.

Mitemcinal

Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

Clevidipine

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Phthalylsulfathiazole

It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

Girentuximab

Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).

Macitentan

Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

Pralnacasan

Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).